A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Part of paid clinical trials in Gilbert, Arizona.
- Sponsor
- Graybug Vision
- Study ID
- NCT03953079
- Phase
- PHASE2
- Status
- Completed
Conditions
- Neovascular Age-Related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Drug: GB-102 — DRUGIntravitreal injection of GB-102
- Aflibercept — DRUGIntravitreal injection of aflibercept (2 mg dose)
Study Details
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
Key Dates
- Start date
- Sep 26, 2019
- Status verified
- Jan 2022
- Primary completion
- Dec 15, 2020
- Completion
- Jun 3, 2021
Study Design
- Enrollment
- 56 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: GB-102 1 mg/1 mgParticipants will receive intravitreal (IVT) GB-102 1 mg in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.
- Experimental: GB-102 2 mg/1 mgParticipants will receive intravitreal (IVT) GB-102 2 mg in the study eye at Baseline, intravitreal (IVT) GB-102 1 mg at Month 6 and sham at Months 2, 4, 8 and 10.
- Active Comparator: Aflibercept 2 mgParticipants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.
Primary Outcome Measure
Time to First Rescue Treatment [ Time Frame: Baseline through 12 months ]
Locations (33)
Find similar trials in Gilbert, AZ
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMDPHASE3 · Recruiting · Jaeb Center for Health Research · Glendale, California